GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences
Published: Mar 26, 2013
Studies have shown that inadequate post-operative blood sugar control in heart surgery patients is associated with an increased risk of major complications and death. GlySure recently completed a trial of its CBGM system on cardiac surgery patients. The study revealed GlySure's technology can be used to continuously measure glucose levels with an extremely high degree of accuracy and repeatability across two-to-five days of a patient's stay in ICU, which is key to effectively implementing TGC.
At the Biovision Investor Conference and IN³ Medical Device 360° Conference, Jones will share results of GlySure's cardiac surgery ICU trial and outline the company's plans for CE regulatory trials, which are set to commence this Spring.
Biovision has selected GlySure as one of 35 life science companies to present to its forum of international capital investors and large healthcare companies seeking partnerships and innovation, while the producers of the (IN³) Medical Device 360° Conference have chosen GlySure as one of 35 early stage companies to appear before its global audience of VCs, top investors and corporate acquirers.
GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). The company has demonstrated through ICU testing highly accurate sensors, which can provide continuous glucose readings throughout the length of a patient's stay in the ICU. GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com